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Abstract
Barrett esophagus is an epithelial metaplasia that predisposes to adenocarcinoma. Better markers of cancer risk are
urgently needed to identify those patients who are likely to benefit most from emerging methods of endoscopic ab-
lation. Disease progression is associated with genomic DNA changes (segmental gains, losses, or loss of hetero-
zygosity). Although these changes are not easily assayed directly, we hypothesized that the underlying DNA
damage should activate a DNA damage response (DDR), detectable by immunohistochemical (IHC) assays of check-
point proteins and the resulting replicative phase cell cycle delays. Surgical specimens and endoscopic biopsies (N =
28) were subjected to IHC for the cell cycle markers cyclin A and phosphorylated histone H3 (P-H3), the DDR mark-
ers γH2AX and phosphorylated ATM/ATR substrates (P-ATM/ATRsub), and the DNA damage-responsive tumor
suppressors p16 and p53. Correlations were made with histologic diagnoses. The fractions of cells that stained for
cyclin A, P-H3, and γH2AX increased in parallel in dysplastic tissue, consistent with checkpoint-mediated cell cycle de-
lays. Foci of nuclear γH2AX and P-ATM/ATRsub were demonstrated by standard and confocal immunofluorescence.
Staining for p16 was more prevalent in early-stage disease with lower staining for γH2AX and P-H3. Staining for p53
was moderately increased in some early-stage disease and strongly increased in some advanced disease, consistent
with checkpoint-mediated induction and mutational inactivation of p53, respectively. We suggest that IHC for DDR-
associated markers may help stratify risk of disease progression in Barrett.
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Introduction
Barrett esophagus is characterized by asymptomatic replacement of
normal squamous esophageal mucosa by intestinal metaplasia. Barrett
is a major risk factor for esophageal adenocarcinoma (EAC), the only
major cancer in the United States to be increasing in incidence. The
population prevalence of Barrett is approximately 1% to 2%, with an
estimated risk of progression to EAC of up to 0.5% per year [1,2]. The
transformation of Barrett to EAC is typically marked by histologically
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defined steps of low-grade dysplasia (LGD) and high-grade dysplasia
(HGD) [3]. However, the natural history of Barrett is unclear [4].
Most patients with documented Barrett participate in endoscopic
biopsy surveillance programs with the goal of early identification of dys-
plastic change and the characterization of its severity. Although widely
pursued, surveillance is of questionable utility [5]. Its benefit is limited
by biopsy sampling error and perhaps more importantly, the reliability
of histologic interpretation. Emerging evidence albeit with relatively
short follow-up indicates that radiofrequency ablation can eradicate
most dysplastic Barrett with acceptable morbidity [6]. However, success-
ful therapy typically requires multiple treatment sessions for several
months, and most of these patients would not have progressed to
EAC. Improved markers are needed to direct endoscopic surveillance
and ablation to those patients at high risk of EAC, to avoid unnecessary
intervention and frequent surveillance in those at low risk, and to provide
improved surrogate end points for ablation and chemoprevention trials.
Although the de facto criterion standard, histologic diagnosis is an
imperfect determinant for clinical decision making [5,7,8]. As a result,
many alternative biomarkers of increased risk have been proposed includ-
ing telomere length [9,10], measures of apoptotic control [11], cell pro-
liferation [12], loss of heterozygosity at several loci [13], and variation
in nuclear DNA content [14,15]. Elegant studies have demonstrated
substantial increase in cancer risk for those patients with aneuploidy,
tetraploidy, or loss of heterozygosity of p53 and p16 [13,15,16]. How-
ever, the clinical utility of these molecular markers has been limited and
none has become a standard component of clinical care today.
In the current study, we have examined Barrett tissue for evidence of
a DNA damage response (DDR). Barrett tissue accumulates genomic
changes with advancing dysplasia [9,17]. The highest risk tissue mani-
fests p53 mutations, tetraploidy or aneuploidy, and widespread DNA
copy number changes and loss of heterozygosity, indicative of chromo-
somal rearrangements, deletions, duplications, and/or gene conversion.
Of particular note, recurrent lesions were seen at two DNA “fragile
sites,” which are prone to strand breakage during DNA replication.
Thus, the fragile site lesions and other genomic changes are typically
caused by DNA double-strand breaks and/or other impediments to
replication [18]. Such breaks are normally recognized by cells as a
major threat to genome stability and cell viability and are met with a
robust DDR.
We therefore hypothesized that DNA double-strand breaks and other
impediments to DNA replication occur frequently in Barrett cells, are
met with a DDR, and drive neoplastic progression. We sought evidence
for a DDR in Barrett tissue, using molecular markers for the DDR and
associated cell cycle phase delays and tumor suppressor gene activation.
We emphasized methods that might be reproduced by most pathology
laboratories and, thus, may prove to be clinically practical.
Materials and Methods
Tissue Acquisition
Banked Barrett tissues were used according to internal review board
protocols at Fox Chase Cancer Center (FCCC), Cleveland Clinic, and
Temple University. Surgical specimens were from FCCC, resected for
HGD or EAC. The prospective portion of the study was performed at
FCCC with separate internal review board approval. Informed consent
was obtained from all patients. Patients were recruited who were sched-
uled for diagnostic endoscopy for newly diagnosed Barrett esophagus
or surveillance endoscopy and endoscopic ablation for a known history
of Barrett esophagus and/or associated intramucosal EAC. Additional
biopsies were obtained beyond those taken for usual care. Samples were
fixed in formalin and embedded in paraffin. Although collected from
different institutions, the endoscopic samples were all read by one
pathologist (H.C.).
Antibodies, Immunohistochemistry, and Immunofluorescence
Immunohistochemistry (IHC) was performed using the following
antibodies (Abs): Cyclin A (NCL-cyclin A; Novocastra Laboratories
Ltd, Newcastle upon Tyne, UK), P-H3 Ser10 (no. 9701; Cell Signaling
Technology, Inc, Danvers, MA), P-(γ)H2AX Ser139 (Upstate 05-636;
Millipore, Billerica,MA), P-ATM/ATR substrates (no. 2851; Cell Signal-
ing Technology, Inc), p16 (JC2, a mouse monoclonal Ab that recog-
nizes the first ankyrin repeat of p16; gift of Jim Koh, Duke University,
Durham, NC), and p53 (NCL-p53-DO7; Novocastra Laboratories
Ltd). IHC was performed by standard procedures using formalin-fixed,
paraffin-embedded sections with antigen retrieval (microwave treatment
in citric acid buffer). We used the avidin/biotin detection system with
hematoxylin counterstain. Images were captured electronically [19],
and cells with staining clearly above background were scored as positive.
For validation of the IHC Abs using cultured cells, U2-OS osteogenic
sarcoma cells were subjected to the designated treatments. Protein ex-
tracts and cells for IHC were prepared in parallel. Cells were embedded
in Histogel (see below), fixed in formalin, embedded in paraffin, and
sectioned as per the tissue samples.
Indirect immunofluorescence was performed by standard procedures
using antigen retrieval by microwave treatment [20]. Secondary Abs
used were Alexa Fluor 488 and 568 (Invitrogen, Carlsbad, CA). Nuclei
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).
Images were obtained using a standard epifluorescence (Nikon, Melville,
NY; TE300 inverted microscope with mercury bulb) and confocal
microscopes (Nikon Eclipse 2000TE inverted confocal microscope
with C1si scanhead) with separate channels (laser lines 406 [DAPI],
488 [green], and 561 [red]).
Culture, Immunoblot Analysis, and Histologic Processing of
U2-OS Cells
To validate the Abs used for immunohistochemistry, a U2-OS human
osteogenic sarcoma cell line with inducible expression of p16 was cul-
tured and subjected to immunoblot analysis as described [21], using
the same Abs used for immunohistochemistry. Standard culture condi-
tions included 1μg/ml tetracycline to repress p16 expression. The follow-
ing conditions were used to generate “low” and “high” levels of expression
of each antigen. Cyclin A: low, treatment with 40 ng/ml nocodazole for
24 hours followed by two washes with phosphate-buffered saline and
culture without drug for 4 hours; high, treatment with 4μMhydroxyurea
(HU) for 24 hours. P-H3: low, treatment with HU for 24 hours; high,
nocodazole for 24 hours. γH2AX: low, standard culture; high, 50 μM
etoposide for 24 hours. p16: low, standard culture conditions, with tetra-
cycline; high, culture without tetracycline for 24 hours. p53: low, stan-
dard culture conditions; high, etoposide for 24 hours. Protein extracts
were prepared in E1A lysis buffer. For immunohistochemistry, cells were
scraped form the plate, pelleted by brief centrifugation, fixed in for-
malin for 5 minutes, solidified in a drop of Histogel (Thermo-Fisher,
Waltham, MA), embedded in paraffin, and sectioned as per tissue.
Immunohistochemical staining was performed as per the tissue samples.
Statistical Analysis
Proportions of cyclin A–positive and P-H3–positive cells in samples
with or without dysplasia were compared with two-sampleWilcoxon rank
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sum tests. Two-sided P values were calculated for the null hypothesis
of equal distributions and the alternative that the dysplastic distribu-
tion differed by a shift from the nondysplastic distribution. For compari-
son of γH2AX staining in nondysplastic and dysplastic samples, the
Jonckheere-Terpstra test was applied to the data presented in Table 1.
The statistical software used was written at our institution by one of
the authors (S.L.). Further details are available upon request.
Results
Predicted Cell Cycle Phase Shifts
A DDR imposes delays within replicative phases of the cell cycle—S
and G2. These delays permit DNA repair before progression through
mitosis fixes the mutations in progeny or mediates mitotic catastrophe
[18,22]. Cyclin A is expressed in S and G2 phases and degraded in
early mitosis. Given that early mitosis is short (<30 minutes) compared
with S and G2 phases (8-12 hours), cyclin A expression can be used as
a marker for the latter phases. Increased expression of cyclin A near the
esophageal lumen has been documented to correlate with degree of
dysplasia in Barrett epithelium and taken as evidence for increased cell
proliferation [12]. We hypothesized that a DDR contributes to the
prevalence of cyclin A expression in Barrett.
Although the DDR delays mitotic entry, it might eventually increase
the mitotic index. Such a scenario has been documented after a pro-
longed premitotic delay enforced by overexpression of the spindle
checkpoint protein Mad2 [23]. Subsequent mitotic progression was in-
efficient, causing an increase in the mitotic fraction. This was thought
to reflect decay of key mitotic factors during the prolonged G2 arrest.
Thus, DDR checkpoint arrest may also result in mitotic delays and
increased mitotic fractions. In addition, checkpoint responses typically
mediate delays rather than enduring arrests. Cells with excessive damage
may eventually slip into mitosis despite the presence of unreplicated
or unrepaired DNA, resulting in defective sister chromatid separation
(“anaphase bridges”) and delayed mitosis [23,24]. Phosphorylation at
Ser10 of histone H3 (P-H3) has been shown to tightly correlate with
mitosis [25] and can be detected by IHC. We therefore reasoned that
progression in Barrett might be associated with increased P-H3 staining.
For IHC, we chose Abs that have been established in the literature.
In addition, we validated these reagents using cultured human cells syn-
chronized in different cell cycle phases. In parallel, one culture was used
to prepare protein extracts and assayed by immunoblot analysis, while
the other was fixed, embedded, sectioned, and subjected to IHC with
the same Ab. Low and high levels of cyclin A and P-H3 detected by
immunoblot analysis were reflected in low and high levels of IHC stain-
ing, respectively (Figure 1, A–F ).
Surgical Resection Specimens
We obtained Barrett tissues representing a broad spectrum of pa-
thology, from simple Barrett to frank EAC. We began by examining
surgical resection specimens from patients with HGD or EAC for IHC
markers of replicative phases. Cyclin A expression was higher in Barrett
tissue with dysplasia or EAC (Figure 2, C and E) than Barrett with
no dysplasia (Figures 2A and 3A; P < .04), consistent with increased
cell proliferation and/or replicative phase delays in dysplasia. Similarly,
staining for P-H3 was minimal in nondysplastic Barrett (Figure 2B)
but was readily detected in dysplasia or EAC (Figures 2, D and F,
and 3A; P < .006). Thus, in this small series, dysplastic Barrett demon-
strated an increase in cells within replicative phases, and P-H3 staining
was a better discriminant for dysplasia than cyclin A staining.
γH2AX Formation
The DDR is characterized by activation of the ataxia telangietasia
mutated (ATM) and ATM and Rad3-related (ATR) kinases [18].
ATM and ATR phosphorylate the variant histone H2AX on Ser129,
generating its γ form in chromatin surrounding DNA lesions [18,22].
γH2AX formation is one of the most sensitive and specific markers of
the DDR and is thought to foster a permissive local environment for
recruitment and activation of other DDR proteins. To validate our
γH2AX IHC by immunoblot analysis, we prepared cell cultures with
and without treatment with etoposide, a topisomerase inhibitor known
to induce double-strand DNA breaks. Etoposide treatment resulted in
higher levels of γH2AX by both assays (Figure 1, G–I).
We tested the surgical resection tissues for activation of the DDR by
IHC forγH2AX [26]. As expected, staining forγH2AX in nuclei was not
as uniform as that for cyclin A and P-H3, so it could not be as precisely
quantified. Nonetheless, nuclear γH2AX staining was readily detected in
Barrett epithelium and was generally stronger in dysplasia or EAC than in
nondysplastic Barrett tissue (Figure 2, G and H ; data not shown).
Endoscopic Biopsy Specimens
We next tested whether these assays could be extended to endoscopic
biopsies from patients undergoing routine screening or surveillance for
dysplasia in Barrett. Such samples are used to stratify risk by pathologi-
cal analysis and include tissues from patients who have not manifested
HGD or EAC.
Cyclin A and P-H3 staining again correlated with dysplasia (Fig-
ure 3B, P < .06 and P < .02, respectively, Figure 4, A–D). In these analy-
ses, samples diagnosed as indefinite for dysplasia were grouped with
frankly dysplastic tissue, as is the norm, but the results remained signifi-
cant when the indefinite samples were excluded (P < .04 and P < .02,
respectively; data not shown). Again, P-H3 staining demonstrated a
somewhat greater difference between nondysplastic and dysplastic
groups than cyclin A staining (Figure 3B). γH2AX staining was dis-
tinctly increased in nuclei in some samples (Figure 4, E and F ; Table 1).
A strong trend was observed toward increased γH2AX staining in
dysplastic samples, with only three of nine nondysplastic samples show-
ing moderate γH2AX staining versus six of seven dysplastic samples
(Table 1; P < .06).
Table 1. IHC of Molecular Markers in Barrett Endoscopic Biopsies by Dysplasia Grade.
Sample Pathology Cyclin A* P-H3† γH2AX* p16* p53*
1 No dysplasia ++ ++ − ++ −
2 No dysplasia ++ ++ + + −
3 No dysplasia +++ + ++ − ++
4 No dysplasia +++ + ++ ++ +
5 No dysplasia + + − − +
6 No dysplasia + + ++ − −
7 No dysplasia ++ NA + ++ −
8 No dysplasia ++ + + + −
9 No dysplasia ++ ++ + − −
10 Indefinite for dysplasia ++ ++ ++ − −
11 Indefinite for dysplasia + + ++ + +
12 Indefinite for dysplasia ++ +++ ++ − −
13 Indefinite for dysplasia +++ ++ + +++ −
14 LGD +++ +++ ++ − −
15 HGD +++ +++ ++ − +++
16 HGD, EAC +++ +++ ++ − +++
NA indicates not available.
*+ indicates staining in 1% to 5% of cells; ++, 6% to 20%; +++, more than 20%.
†+ indicates staining in 0.5% to 1.9% of cells; ++, 2% to 3%; +++, more than 3%.
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Phosphorylated ATM/ATR Substrates
We then assayed the DDR in Barrett tissue by a second method.
ATM and ATR phosphorylate many additional substrates involved
in the DDR. Among them are p53, p95/NBS1, MDM2, Chk2,
BRCA1,CtIP, 4E-BP1, andChk1 [22]. Peptide sequences with a hydro-
phobic residue followed by serine or threonine and then glutamine are
preferred sites of ATM/ATR phosphorylation [27,28]. Antibodies di-
rected against the phosphorylated forms of these peptides (P-ATM/
ATRsub) have proven useful in detecting ATM/ATR–phosphorylated
substrates, providing another marker of the DDR. We examined
P-ATM/ATRsub reactivity by IHC. Barrett epithelial cells generally
showed greater P-ATM/ATRsub than surrounding tissue, and a fraction
of nuclei showed distinct nuclear staining (Figure 4, G and H ).
p16 and p53 as DNA Damage-Responsive Tumor Suppressors
The two dominant tumor suppressors that are inactivated in Barrett—
p16Ink4a and p53—can be induced by DNA damage, albeit with mark-
edly different kinetics [29,30]. Thus, these proteins may be induced in
Barrett by the DDR. p53 is the classic tumor suppressor induced by the
DDR but can be induced by other stimuli [31–33]. In settings of large
external genotoxic insults, such as high-dose irradiation, p53 induction
can contribute to a G1-S block. However, induction during replicative
stress results in G2 arrest and, variably, apoptosis. Previous studies have
documented p53 staining in some Barrett biopsies, although its rela-
tionship to a DDR has not been addressed [34–36]. Diffuse, high-level
staining has been shown to correlate with p53 mutation in advanced
disease (HGD or EAC) and to have some predictive power in LGD
Figure 1. Validation of IHC staining. We exposed U2-OS cell clones with inducible expression of p16 to conditions predicted to yield low
and high expression, respectively, of each target antigen (see Materials and Methods for additional details). Cells were processed in
parallel for IHC (left, center) or immunoblot analysis (right (C, F, I, L, O)). The conditions were as follows. Cyclin A: low (A), synchrony in
G1 using a mitotic arrest in nocodazole (Noc) followed by release for 4 hours; high (B), G1/S arrest mediated by hydroxyurea (HU). P-H3: low
(D), G1/S arrest in HU; high (E), mitotic arrest in Noc. γH2AX: low (G), standard culture; high (H), induction of DNA double-strand breaks by
etoposide. p16: low (J), standard culture (in tetracycline); high (K), withdrawal of tetracycline. p53: low (M), standard culture conditions; high
(N), etoposide. Immunoblot analysis for tubulin (tub) served as a loading control. In immunoblots (I) and (O), intervening lanes (from an
intermediate induction condition not shown) were removed digitally.
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[37–39]. However, some p53 mutations in Barrett-associated neoplasia
truncate the protein, ablating its stable expression [34]. Therefore, p53
IHC alone cannot reliably detect advanced disease.
Although the regulation of p16 is incompletely understood, p16 is
known to contribute to a cell cycle arrest mediated by the DDR [40];
we have found that p16 can be induced by DNA damage in a variety of
primary human cells [30]. p16 is commonly inactivated during progres-
sion of Barrett esophagus [41–43], consistent with the notion that it
restrains disease progression. Inactivation usually occurs by promoter
methylation and is a relatively early event, preceding development of
tetraploidy aneuploidy [17,44,45]. Limited IHC studies have shown
p16 expression in some Barrett tissue [46,47] but have not examined
its correlation with dysplasia or a DDR.
We assayed p16 expression by IHC, using conditions that we have
extensively validated [20]. These conditions were further validated by
induction of p16 in a cell line null for endogenous p16 expression
(Figure 1, J–L). We observed a trend toward greater p16 detection in
nondysplastic biopsy samples: five of nine samples with no dysplasia
showed staining compared with two of seven dysplastic samples, with
both p16-positive samples in the latter group scored as “indefinite” for
Figure 2. Increased cyclin A, P-H3, and γH2AX staining in Barrett-associated dysplasia within surgical resection specimens. Esophageal
resection specimens from patients with HGD or EAC were subjected to IHC staining (brown) and counterstained with hematoxylin (blue).
(A, B) Tissuewith no dysplasia (ND). Cyclin A staining (A) is confined to nuclei of cells in basal regions of intestinal-like crypts. Note the goblet
cells of Barrett. P-H3 staining (B) is rare. (C, D) LGD: Cyclin A and P-H3 staining are more prevalent. (E, F) EAC: Cyclin A and P-H3 staining are
prevalent. (G) γH2AX staining is higher in EAC (left) than neighboring Barrett tissue without dysplasia (ND, right). (H) LGD: Scattered cells
display distinct nuclear γH2AX staining.
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dysplasia (Figure 4, I and J ; Table 1). Only two of seven samples with
p16 staining had moderate (++) γH2AX staining, and most had low (+)
γH2AX staining. None had high (+++) P-H3 staining, suggesting that
entry into mitosis may be restrained in p16-expressing tissue. Thus, a
substantial fraction of nondysplastic or minimally dysplastic tissue de-
tectably expressed p16. These tissues generally have evidence for only
low-moderate DDR and none had high a mitotic index. We hypothe-
size that these represent lower-risk tissues, with a functional DDR.
We found that staining for p53 in Barrett biopsies increased with dys-
plastic progression (Figures 1,M–O, and 4, K and L), as previously de-
scribed [35,46]. Moreover, we observed two distinct patterns of p53
expression (Figure 4, K and L; Figure 5; Table 1). Uniform high-level
staining was seen in some samples with HGD or EAC, consistent with
mutational inactivation of p53 that results in stabilization of the pro-
tein (Figure 5C). Moderate p53 staining was observed in some samples
with LGD, clearly before establishment of homogeneous neoplastic
cell population (Figure 5A). This latter pattern is consistent with func-
tional p53 induction, potentially secondary to a DDR. Consistent with
this notion, most (five of six) tissues with p53 staining had moderate
γH2AX staining (Table 1). We hypothesize that these examples repre-
sent a strong DDR and stimulus for p53 induction. Note that some
of these tissues either did not manifest dysplasia (Table 1, samples 3
and 4) or were indefinite for dysplasia (sample 11). We surmise that
these tissues harbor increased risk for malignant progression, despite
relatively benign pathology. Additional trends emerge when p16 and
p53 staining results are combined. No samples (none of five) that
showed p16 staining without p53 staining had greater than trace (+)
γH2AX, whereas most (three of four) samples with p53 staining but
no p16 staining did. Thus, use of p53 as part of a small panel of
DDR-related markers may provide a more comprehensive picture of
progression risk.
Immunofluorescence for Nuclear DDR Foci
As a further test for DDR in Barrett biopsies, we performed im-
munofluorescence for γH2AX and pATM/ATRsub. This staining
would not be clinically practical but can detect these antigens in dis-
crete nuclear foci. Such foci represent hallmarks of the DDR in cul-
tured cells exposed to acute genotoxic insults [26,48]. Although
background staining in the formalin-fixed tissue was greater than that
typically seen in cultured cells, we observed individual Barrett cells
with high nuclear γH2AX staining (data not shown), consistent with
the IHC findings. Moreover, coimmunofluorescence staining dem-
onstrated Barrett biopsies with distinct nuclear foci costaining for
γH2AX and pATM/ATRsub (Figure 6, A–D). Confocal microscopy
confirmed the nuclear location of the foci (Figure 6, E–H ).
Discussion
We have presented evidence for a DDR in Barrett esophagus, character-
ized by staining for γH2AX and P-ATM/ATRsub, replicative phases of
the cell cycle, and the DNA damage-responsive tumor suppressors p16
and p53. These markers were evident in surgical resection specimens,
Figure 3. Quantitation of increased cyclin A and P-H3 staining in Barrett surgical specimens and endoscopic biopsy samples with dysplasia.
(A) Surgical specimens. IHC was performed on formalin-fixed specimens (N = 6). Approximately 267 to 938 epithelial cells were counted
per stained tissue sample (from three to four 10× microscope fields per specimen), and the percentage of (+) cells were determined
(16,979 cells were counted in total). The results are graphed in “box and whisker” plots of the mean, upper and lower quartiles (boxes),
and SDs (thin lines). Tissue with no dysplasia (ND) was compared with tissue with dysplasia (LGD, HGD, and EAC). Cyclin A and P-H3
staining was significantly higher in the dysplastic tissues (P < .02 and P < .003, respectively). (B) Endoscopic biopsy samples. Cyclin A
and P-H3 staining was scored in 20× microscope fields from endoscopic biopsies with no dysplasia (left) or indefinite for dysplasia
(IND)/LGD/HGD (right) and graphed as in (A). A total of 8763 cells from tissues with ND (N = 8) and 9247 cells from tissues with IND/
LGD/HGD (N = 7), respectively, were scored for cyclin A staining. A total of 8799 cells from tissues with ND and 10,121 cells from tis-
sues with IND/LGD/HGD, respectively, were scored for P-H3 staining. Cyclin A and P-H3 staining were significantly higher in the dysplastic
biopsies (P < .03 and P < .01, respectively).
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endoscopic biopsies, and cytological brushings (data not shown). Some
cells show a broad increase in nuclear staining for γH2AX and P-ATM/
ATRsub. Others show distinct nuclear foci, confirmed by confocal
microscopy. Staining for these markers is increased in dysplasia, con-
sistent with evidence for development of widespread genomic DNA
changes (deletions, gains, loss of heterozygosity) during disease progres-
sion in Barrett [17]. This DNA damage may be caused by replication
under conditions of stress, such as sustained replication per se, exposure
to genotoxic bile and acid [49], oncogene activation [50,51], reactive
oxygen species [52], and telomere erosion [9]. We propose that DNA
damage drives neoplastic progression and is countered by the DDR.We
suggest that induction of p16 and p53, two major tumor suppressors
that are inactivated in Barrett, is driven in part by the DDR and that
disease progression is accelerated when these tumor suppressors are in-
activated by promoter methylation (p16) or mutation (p16 and p53),
relieving associated cell cycle inhibition and apoptosis.
Trends were observed for correlation between DDR and replicative
phase markers. Increased cyclin A staining in surface metaplastic epi-
thelium has been documented previously to correlate with advancing
dysplasia in Barrett [12], where it was viewed as a marker of cell pro-
liferation. We suggest that increased cyclin A staining may also reflect S
and G2 delays mediated by the DDR.We have found examples of tissue
without dysplasia in which the fraction of cells that stain for cyclin A is
as high or higher than inmost cases of HGD or EAC but P-H3 staining
is low and p53 staining is observed (Table 1, samples 3 and 4). This
finding may reflect the operation of an intact DDR, with functional
delays in S and G2 progression mediated by cyclin-dependent kinase
inhibition. With increasing DNA damage and loss of functional p16,
p53, and perhaps other DDR effectors, unrestrained S and G2 progres-
sion may result in a lower fraction of cells in those cell cycle phases and
an increased mitotic fraction. Consistent with this notion, P-H3 stain-
ing was high in most cases of HGD and EAC (cf., Table 1). Increased
P-H3 staining in fact showed a modestly better correlation with dys-
plasia than cyclin A staining (Figures 2–4).
Although we have established a correlation between DDR and asso-
ciated cell cycle markers on the one hand and pathological diagnosis
on the other, the latter is widely recognized as an imperfect, default
criterion standard. A key question now is whether these molecular
markers can improve prediction of EAC risk beyond that provided
by histologic diagnosis alone. A larger prospective study will be required
to address this issue. However, we note that, in the examples shown
in Figure 3, absence of p16 staining and increased γH2AX, P-ATM/
ATRsub, and p53 staining distinguished the Barrett sample without dys-
plasia but with a history ofHGD from the sample with simple Barrett (no
history of advanced disease). Thus, a small panel of DDR markers may
identify tissue at increased risk, despite absence of dysplastic morphology.
Figure 4. Increased staining for replicative cell cycle phases, DDR,
p16, and p53 in Barrett endoscopic biopsy samples. Nearby formalin-
fixed sections were stained from samples with no dysplasia and no
history of HGDor EAC (left) or no dysplasia butwith a history of HGD
(right). Sections were stained for (A, B) cyclin A, (C, D) P-H3, (E, F)
γH2AX, (G, H) pATM/ATRsub, (I, J) p16, and (K, L) p53. p16 staining
wasmore prominent in the specimenwith Barrett alone (I), whereas
pATM/ATRsub (H) and p53 (L) staining were more prominent in the
sample with a history of HGD.
Figure 5. Two patterns of p53 staining in Barrett tissue. Endoscopic
biopsies were subjected to IHC for p53. (A) LGD showing moderate
p53 staining in nuclei of scattered cells. Note the diversity of cell
types in the epithelium, indicating that this tissue is not neoplastic.
(B) No p53 staining in a sample with no dysplasia (ND). (C) Uni-
formly high p53 staining in a sample with uniform cell morphology
indicative of HGD or EAC.
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A definitive test of this notion will require a larger sample set and lon-
gitudinal follow-up data.
In summary, we have presented evidence for a DDR in Barrett
esophagus based on staining for γH2AX and P-ATMR-ATR, elevated
fractions of cells in replicative phases, and expression of DDR-associated
tumor suppressors. We observed increased staining for cyclin A and
P-H3 in dysplastic tissue, consistent with the notion that DNA dam-
age and the DDR impose replicative phase delays. We observed trends
toward p16 staining in tissues with little or no dysplasia and p53 stain-
ing in tissues with increasing dysplasia. Finally, examples were found of
tissue without dysplasia that manifested high cyclin A, P-H3, γH2AX,
and/or p53 staining. We suggest that these markers might add value
to pathological diagnosis in identifying high-risk tissue andmerit testing
in a larger set of tissues and in patients with longitudinal follow-up.
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Figure 6. Immunofluorescence staining of nuclear DNA damage foci in Barrett tissue. (A–D) An endoscopic biopsy sample that showed no
dysplasia but displayed IHC staining for γH2AX and P-H3 and was from a patient with a history of intramucosal carcinoma was subjected to
coimmunofluorescence staining for γH2AX (A), P-ATM/ATRsub (B), and DAPI staining for nuclear DNA (C). The combined image is shown in
(D). Arrows: nuclear foci costaining for γH2AX and P-H3. Control stains without primary Abs showed no nuclear foci (not shown). (E–H)
Confocal microscopy confirmed the nuclear location of the costained foci (arrows). Magnification denoted by scale bars in (D) and (H).
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